The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

9 articles for M Missbach


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists).EBI
Novartis Institutes For Biomedical Research
1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.EBI
Novartis Institutes For Biomedical Research
Novel scaffold for cathepsin K inhibitors.EBI
Novartis Institutes For Biomedical Research
Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.EBI
Novartis Institutes For Biomedical Research
7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.EBI
Novartis Pharma Research
7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.EBI
Novartis Pharma Research
Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src.EBI
Novartis Pharma
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.BDB
Glaxosmithkline
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.BDB
Astrazeneca